, Volume 19, Issue 1, pp 204-205
Date: 30 Mar 2013

Fibromyalgia and breast cancer

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Dear Editor,

The article entitled "Frequency of fibromyalgia syndrome in breast cancer patients" by Akkaya et al. [1], published online in 2012 in your journal, was quite interesting. We perceived the article as an important topic while screening the literature for our own study in which we are researching the frequency of fibromyalgia (FM) in patients with non-metastatic colorectal cancer. According to the title, we thought that the article defining the prevalence of FM in breast cancer was considerable. Therefore, we wanted to emphasize some points.

In this article by Akkaya et al. [1], we first want to point to the missing "adjuvant" terminology. Tamoxifen and aromatase inhibitors (AIs) are part of adjuvant "endocrine" treatment in patients with early-stage breast cancer (ESBC). We would like to draw your attention to the fact that the adjuvant terms for chemotherapy and radiation treatment given to the patients were not expressed clearly. For this reason when the article was first re

This comment refers to the article available at doi:10.1007/s10147-012-0377-9.
An author’s reply to this comment is available at doi:10.1007/s10147-013-0546-5.
An author's reply to this comment is available at http://dx.doi.org/10.1007/s10147-013-0546-5.
This comment refers to the article available at: http://dx.doi.org/10.1007/s10147-012-0377-9.